巨子生物控股有限公司（股票代码：2367）于2026年1月5日公告，基于翌日披露报表信息，公司于同日进行股份回购，涉及40万股普通股，约占其已发行股本的0.0374%。每股回购价介乎港币33.74元至港币34.28元，总回购金额约为港币13,581,608元。
本次回购并未导致公司已发行股份变动，截至公告日，公司已发行股本仍为1,070,904,000股。此次回购依据2025年6月13日股东大会通过的回购授权开展，授权可回购股份总数为107,090,400股。截至目前，公司已于交易所或其他场内渠道累计回购5,600,000股，占授权通过当日公司已发行股份总数的0.5229%。
公司在公告中确认，相关交易已遵守香港联合交易所有限公司证券上市规则等相关法律与规定。公告由执行董事兼联席公司秘书严鈺博代表公司签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.